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ABSTRACT
Metastasis is the cause of most prostate cancer (PCa) deaths and has been 
associated with circulating tumor cells (CTCs). The presence of ≥5 CTCs/7.5mL of 
blood is a poor prognosis indicator in metastatic PCa when assessed by the CellSearch® 
system, the “gold standard” clinical platform. However, ~35% of metastatic PCa 
patients assessed by CellSearch® have undetectable CTCs. We hypothesize that 
this is due to epithelial-to-mesenchymal transition (EMT) and subsequent loss of 
necessary CTC detection markers, with important implications for PCa metastasis. Two 
pre-clinical assays were developed to assess human CTCs in xenograft models; one 
comparable to CellSearch® (EpCAM-based) and one detecting CTCs semi-independent 
of EMT status via combined staining with EpCAM/HLA (human leukocyte antigen). 
In vivo differences in CTC generation, kinetics, metastasis and EMT status were 
determined using 4 PCa models with progressive epithelial (LNCaP, LNCaP-C42B) 
to mesenchymal (PC-3, PC-3M) phenotypes. Assay validation demonstrated that 
the CellSearch®-based assay failed to detect a significant number (~40-50%) of 
mesenchymal CTCs. In vivo, PCa with an increasingly mesenchymal phenotype shed 
greater numbers of CTCs more quickly and with greater metastatic capacity than 
PCa with an epithelial phenotype. Notably, the CellSearch®-based assay captured the 
majority of CTCs shed during early-stage disease in vivo, and only after establishment 
of metastases were a significant number of undetectable CTCs present. This study 
provides important insight into the influence of EMT on CTC generation and subsequent 
metastasis, and highlights that novel technologies aimed at capturing mesenchymal 
CTCs may only be useful in the setting of advanced metastatic disease.
INTRODUCTION
Prostate cancer (PCa) is the most commonly 
diagnosed cancer and second most common cause of 
cancer death in American men [1]. The majority of 
prostate cancer deaths result from metastasis, since current 
therapies are non-curative in the metastatic setting [2]. 
Detection of circulating tumor cells (CTCs) in the blood 
is correlated with metastatic disease burden and reduced 
overall survival [3–6], with ≥5 CTCs/7.5ml of blood being 
indicative of poor prognosis in metastatic PCa patients 
[6]. Additionally, changes in CTC number throughout 
treatment have been demonstrated to reflect therapy 
response [7].
Due to the rare nature of CTCs (~1 CTC/105-107 
leukocytes in metastatic patients), extremely sensitive 
technologies are required for accurate CTC detection 
[8]. Several techniques have been employed to enrich 
                  Research Paper
Oncotarget76126www.impactjournals.com/oncotarget
CTCs including size- and/or density-based separation, 
and antibody-based techniques with/without the aid of 
microfluidics, while detection techniques rely almost 
exclusively on protein- (immunofluorescence/flow 
cytometry) or nucleic acid-based (RT-PCR/qRT-PCR) 
assays [9, 10]. Each approach has unique advantages and 
disadvantages; however most lack the standardization 
and quality control required for routine clinical use. The 
CellSearch® system (CSS; Janssen Diagnostics) provides 
a standardized method for sensitive detection and 
quantification of CTCs in human blood. It is the only CTC 
assay approved by the U.S. Food and Drug Administration 
for clinical management of metastatic prostate, breast, and 
colon cancer patients [4–6], and is thus considered the 
“gold standard” CTC platform.
The CSS distinguishes CTCs from leukocytes 
through immunomagnetic selection of cells with an 
EpCAM+ (epithelial cell adhesion molecule) phenotype 
followed by differential fluorescent staining for 
cytokeratins (CK) 8/18/19, CD45 (leukocyte marker), 
and DNA (4’,6-diamidino-2-phenylindole [DAPI]). 
Although the CSS has been used to effectively enumerate 
CTCs in the blood of metastatic PCa patients [6], CTCs 
are undetectable in ~30% of these patients despite the 
presence of systemic disease [11]. This suggests that 
either CTCs are truly not present in ~1/3 of metastatic PCa 
patients; or that CTCs are present but undetectable by the 
CSS because they do not meet the standard CTC definition 
(EpCAM+/CK+/DAPI+/CD45-). It has been proposed 
that this lack of detection may be due to the epithelial-
to-mesenchymal transition (EMT) [12–14], a dynamic 
cellular process that leads to downregulation of epithelial 
markers necessary for CTC capture/enumeration, 
including EpCAM/CK [12, 15, 16]. Corresponding 
increases in mesenchymal markers (N-cadherin/vimentin/ 
fibronectin) and resulting changes in cellular morphology 
have been shown to enhance cancer invasion, metastasis, 
therapy resistance, and disease aggressiveness [12, 17]. 
The standard CSS definition of CTCs may therefore be 
missing the most invasive and highly metastatic cells 
driving disease progression. In support of this, several 
studies have demonstrated that CTCs with a purely 
mesenchymal phenotype are undetectable by the CSS, 
but that the presence of mesenchymal marker expression 
on CTCs with a hybrid epithelial-mesenchymal (E-M) 
phenotype is indicative of poor prognosis [15, 18–21]. 
This suggests that current clinical CTC assays may be 
limiting our ability to capitalize on the full potential of 
CTCs, and that a greater understanding of CTC biology is 
necessary in order to guide future technology development 
and translation to the clinic.
The field of CTC research is quite unique in that 
it has evolved using a “bedside-to-bench” path rather 
than the more traditional “bench-to-bedside” model of 
translational research. Although this has allowed for 
quick entry of CTC technology into the clinic, outstanding 
questions regarding the biology of CTCs has resulted in 
a hesitance for their widespread adoption as biomarkers 
for directing patient care. Unfortunately, appropriate 
experimental tools needed to address these outstanding 
biology questions have been largely lacking, especially 
those that mimic the approach utilized by the clinically-
used CSS. This highlights the need for implementation 
of suitable pre-clinical models and development of 
complementary CTC analysis techniques that can assess 
not only the CTCs which are captured using the CSS 
but also those that may be missed, in order to advance 
knowledge. Previous work investigating CTC biology 
in our laboratory using orthotopic xenograft models 
demonstrated that CTC dissemination occurs relatively 
early in the metastatic cascade and that CTCs can be 
generated by both primary tumors as well as metastases 
[22–24]. However, very little is currently known about the 
functional role of EMT in CTC generation, detection and 
metastasis, particularly in the context of prostate cancer.
In this study, we hypothesized that the EpCAM-
based CSS assay is unable to detect CTCs that have 
undergone EMT, and that EMT-related phenotypic 
differences in CTCs have important implications for PCa 
disease progression. To test this, we developed two pre-
clinical assays for assessing human CTCs in xenograft 
models; one that is comparable to the EpCAM-based CSS 
(dependent on EMT status) and one that detects CTCs 
semi-independent of EMT status via negative depletion 
of CD45 and combined staining with EpCAM and HLA 
(human leukocyte antigen). Using these assays, differential 
in vivo CTC generation, capture efficiency, kinetics and 
metastasis were assessed using 4 human PCa cell lines 
(LNCaP, LNCaP C4-2B, PC-3, PC-3M) of increasing 
aggressiveness in pre-clinical orthotopic models of PCa. 
The novel results presented here provide functional 
evidence of the interplay between EMT and CTC biology, 
shedding light on which CTCs are the most important to 
study. This knowledge has the potential to inform ongoing 
CTC technology development and guide strategies for 
the most effective use of CTCs as prognostic/predictive 
biomarkers in clinical oncology.
RESULTS
Human PCa cell lines display differences in 
EMT phenotype
Four human PCa cell lines (LNCaP, LNCaP C4-2B 
[C4-2B], PC-3, PC-3M) previously reported to have 
progressively increasing metastatic capacity [25–28] 
were characterized for epithelial (E-cadherin/EpCAM/
CK) and mesenchymal (N-cadherin/vimentin) markers 
using qRT-PCR, immunoblotting (Supplementary Figure 
S1A, 1B), and flow cytometry (FCM) (Figure 1A). LNCaP 
and C4-2B had consistently higher protein expression 
of epithelial-associated markers E-cadherin and 
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CK8/18/19, while PC-3 and PC-3M had consistently 
higher protein expression of mesenchymal-associated 
markers N-cadherin and vimentin. Although EpCAM 
levels appeared similar between cell lines at the mRNA 
level (Supplementary Figure S1A), differences in EpCAM 
protein expression were evident, with LNCaP and C4-2B 
demonstrating higher levels compared to PC-3 and PC-
3M (Supplementary Figure S1B, Figure 1A). To further 
Figure 1: Human prostate cancer cell lines display differences in EMT phenotype. A. Protein expression analysis by flow 
cytometry for the epithelial-associated markers E-cadherin and EpCAM and the mesenchymal-associated markers N-cadherin and vimentin 
in PC-3M, PC-3, LNCaP C4-2B, and LNCaP human prostate cancer cells. Data are presented as relative fluorescence intensity (expression) 
compared to appropriate positive control cell lines (E-cadherin/EpCAM/CK: MDA-MB-468; N-cadherin/vimentin: HeLa) (n=3). The 
expression of epithelial-associated and mesenchymal-associated proteins corresponds to previously reported cell aggressiveness and in vivo 
metastatic capacity of these cell lines. B. Flow cytometry dot plots of the differential expression of EpCAM (AF488) and CK8/18/19 (PE) 
in investigated prostate cancer cell lines. C. Flow cytometry analysis for co-expression of EpCAM and CK8/18/19, presented as the mean 
± SEM fluorescence intensity of the investigated proteins for each cell line (n=3).
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investigate potential capacity for capture of these cells by 
the EpCAM- and CK-reliant CSS, protein co-expression 
was assessed using FCM (Figure 1B, 1C). This further 
confirmed differential EpCAM expression between cell 
lines, but interestingly demonstrated a similar distribution 
of CK8/18/19 expression, suggesting that any differences 
in CTC capture between cell lines would be due to 
differences in EpCAM expression rather than CK8/18/19.
The ability of E-cadherin to maintain the epithelial 
phenotype and normal adhesive function of cells is 
dependent on its localization to the cell membrane 
[29, 30]. We observed that that although E-cadherin was 
expressed in PC-3, it was aberrantly localized to the 
cytoplasm, likely due to a lack of α-catenin expression 
which is necessary for appropriate E-cadherin membrane 
localization [31]. In contrast, LNCaP and C4-2B strongly 
expressed E-cadherin with appropriate membrane 
localization (Supplementary Figure S2).
CTC recovery using the CSS is significantly 
reduced for PCa cells with a mesenchymal 
phenotype
As the current gold standard CTC detection 
technology in the clinical setting, the CSS relies solely on 
the epithelial-associated marker EpCAM for CTC capture. 
However, EpCAM has been shown to be downregulated 
in cells with an invasive phenotype [32], suggesting that 
EpCAM-based CTC detection techniques such as the 
CSS may be missing a portion of the CTCs that enter the 
bloodstream. To assess this, we developed 2 novel pre-
clinical CTC assays for use with xenograft models; one 
that recapitulates EpCAM-based capture of CTCs by the 
CSS (“EMT-dependent”), which captured CTCs based 
on an EpCAM+/CK+/CD45-/HLA+ phenotype, and one 
designed to detect all the CTCs shed into the circulation 
regardless of EMT status (“EMT semi-independent”), 
capturing CTCs based on a joint human HLA/EpCAM 
approach, including EpCAMlow/- cells (PC-3, PC-3M; 
likely captured primarily by HLA) and EpCAM+ but 
HLAvariable/low cells (LNCaP, C4-2B; likely captured 
primarily by EpCAM). Use of the EMT-dependent assay 
resulted in significantly reduced recovery of CTCs with 
mesenchymal phenotypes (PC-3/PC-3M) when compared 
to CTCs with epithelial phenotypes (LNCaP/C4-2B) 
(p≤0.05) (Supplementary Figure S3A). However, when 
the EMT semi-independent assay was utilized, although 
overall CTC recovery was lower compared to the EMT-
dependent assay, percent recovery was not significantly 
different across cell lines regardless of EMT status 
(Supplementary Figure S3B). The reduced recovery 
demonstrated by the EMT semi-independent assay was 
further investigated by incorporating the additional sample 
handling steps required for the EMT semi-independent 
assay (i.e. red blood cell lysis and additional washes) into 
the EMT-dependent assay. The results demonstrated that 
when using the same reagents and highly epithelial cells 
(C4-2B), addition of extra processing steps resulted in 
equivalent sample loss between matched samples when 
comparing both assays (Supplementary Figure S3C).
Prostate cancer cell lines with an increasingly 
mesenchymal phenotype have an enhanced 
capacity for CTC shedding in vivo and produce 
CTCs that are undetectable by the CSS
LNCaP, C4-2B, PC-3, and PC-3M cells prepared in 
Hank’s buffered saline were injected (1x106 cells/40μL per 
mouse) orthotopically via the right dorsolateral lobe of the 
prostate as described in the Materials and Methods in order 
to assess in vivo CTC generation, kinetics, and detection 
by EMT-dependent versus EMT semi-independent assays, 
and relationship to subsequent metastasis. Using both CTC 
assays, we observed that highly mesenchymal PC-3M shed 
CTCs very quickly post-injection and in greater numbers 
than all other cell lines at most timepoints (p≤0.05) 
(Figure 2A). Additionally, mesenchymal-like PC-3 shed 
a similar number of CTCs as epithelial LNCaP and C4-
2B until week 4 (EMT semi-independent assay) or week 
12 (EMT-dependent assay), at which time the number 
of CTCs increased significantly (p≤0.05). To quantify 
differences in CTC recovery based on EMT status, 
normalized CTC values obtained using both assays from 
each timepoint were generated, and numbers of CTCs 
identified using the EMT-dependent assay were subtracted 
from numbers of CTCs identified using the EMT semi-
independent assay and presented as the mean for each 
timepoint. Positive values represent instances where more 
CTCs were detected with the EMT semi-independent 
assay, whereas negative values represent instances where 
more CTCs were detected with the EMT-dependent assay 
(Figure 2C). We observed that epithelial LNCaP and 
C4-2B had similar CTC recovery across both assays at 
all timepoints investigated. However, mesenchymal PC-3 
and PC-3M showed increased numbers of CTCs recovered 
using the EMT semi-independent assay at later timepoints, 
with significant differences observed when comparing 
PC-3 to LNCaP and C4-2B at 12 weeks (p≤0.05).
Prostate cancer cell lines with an increasingly 
mesenchymal phenotype have enhanced capacity 
for primary tumor formation and metastasis
To determine differences in the extent of disease 
and metastatic spread across the 4 cells lines, at necropsy, 
animals were assessed for primary tumor incidence/
weight, and metastatic spread to lymph nodes and 
distant metastatic sites (lung, liver, bone). We observed 
that primary tumor incidence and size was significantly 
increased in highly mesenchymal PC-3M compared to all 
other cell lines (p≤0.05), except when considering tumor 
weight of PC-3 at 2 weeks (Figure 3A, 3B). All other cell 
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Figure 2: Human prostate cancer cell lines with an increasingly mesenchymal phenotype shed greater numbers of 
CTCs more quickly and have an enhanced in vivo capacity for shedding CTCs that are undetectable by the CellSearch® 
system. PC-3M, PC-3, LNCaP C4-2B, and LNCaP human prostate cancer cells were orthotopically injected into 6-8 week old male nude 
mice via the right dorsolateral lobe of the prostate (1×106 cells/mouse) to assess spontaneous metastasis. At several timepoints post injection 
(2, 4, 8, 12, and 16 weeks) mice were sacrificed and blood (100μl) was collected and processed using both the A. EMT-dependent and B. 
EMT semi-independent assays (50μl/assay) to assess differences in CTC recovery. Data are presented as the mean ± SEM (n=5-12 mice/
group). C. Comparison of the observed difference in the number of CTCs detected using the EMT-dependent and EMT semi-independent 
assays in matched samples. Data are presented as the mean (± SEM) difference in the number of observed CTCs between both assays (# 
captured by EpCAM/HLA assay - # captured by EpCAM assay) at a given timepoint (n=5-12 mice/group). Positive values represent groups 
in which more CTCs were detected with the EMT semi-independent assay, whereas negative values represent groups in which more CTCs 
were detected with the EMT-dependent assay. Differences in the mean number of CTCs between cell lines at a given timepoint using and 
differences between each assay within individual mice was assessed using Wilcoxon Scores followed by a Kruskal-Wallis test at each 
timepoint. Comparison of differences between each assay in matched data sets within cell lines at a given timepoint was performed using a 
Wilcoxon matched-pairs signed rank test. * = significant difference relative to PC-3; α = significant difference relative to LNCaP C4-2B; δ 
= significant difference relative to LNCaP; γ = overall significant difference (unable to perform pairwise comparison) (p≤0.05).
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lines showed comparable primary tumor incidence and 
weight at all timepoints. Additionally, primary tumor 
weight and the number of CTCs shed into the circulation 
(EMT-semi-independent assay) were positively correlated 
for all cell lines (Figure 3C). Immunohistochemical 
analysis of E-cadherin/N-cadherin revealed that all cell 
lines demonstrated comparable epithelial/mesenchymal 
phenotypes in vivo relative to those seen in vitro 
(Figure 3D, Supplementary Figure S4A).
Additional differences between mesenchymal and 
epithelial cell lines were observed in metastatic incidence 
(% of mice developing metastasis) and metastatic burden 
(% of organ occupied by metastatic tumor) to the lymph 
nodes (LN). Microscopy analysis revealed that PC-3M 
had significantly increased incidence of LN metastases 
versus all other cell lines at 4 weeks (p≤0.05), while PC-3 
had significantly increased incidence at 8 and 12 weeks 
compared to C4-2B (p≤0.05). Interestingly, the incidence 
Figure 3: Highly mesenchymal prostate cancer cells exhibit enhanced primary tumor incidence and size and in all cell 
lines CTC number is correlated with primary tumor size. A. Incidence of primary tumor formation following orthotopic injection 
of PC-3M, PC-3, LNCaP C4-2B, and LNCaP human prostate cancer cell lines. Data are presented as the percentage of mice per cell line 
per timepoint with detectable primary tumors (n=6-39 mice/group) as assessed by microscopic histological examination of formalin-fixed, 
H&E stained tissue. * = significantly different (p<0.05), ** (p<0.01), *** (p<0.001). B. Mean combined weight of prostate and bladder at 
time of sacrifice following orthotopic injection of prostate cancer cell lines. Data are presented as the mean ± SEM (n=6-39 mice/group). 
C. Mean normalized number of CTCs/50μl of blood (assessed using the EMT semi-independent assay) correlates with the primary tumor 
weight in all cell lines. D. Representative H&E and IHC (E-cadherin and N-cadherin) images of primary prostate tumors for each cell line 
(40x; scale bars = 50 μm). Primary tumor weights were assessed for cell line variances using Levene’s test, followed by a 1-way ANOVA 
with Tukey’s post-test for multiple comparisons. Spearman rank correlation was utilized to examine the relationship between mean number 
of CTCs and primary tumor weight. * = significant difference relative to PC-3; α = significant difference relative to LNCaP C4-2B; δ = 
significant difference relative to LNCaP (p≤0.05).
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of metastases to LN did not differ significantly between 
PC-3 and LNCaP (Supplementary Figure S5A). However, 
PC-3 did demonstrate significantly increased metastatic 
burden compared to C4-2B at 8 and 12 weeks (p≤0.05) 
(Supplementary Figure S5B). Therefore, although these 
cell lines appear to have a similar capacity to disseminate 
to LN, they do not have the same capacity for subsequent 
growth in this organ. Finally, LNCaP demonstrated 
significantly increased metastatic burden compared to C4-
2B at 12 weeks (p≤0.05). Representative H&E and IHC 
analysis of LN metastases are shown in Supplementary 
Figure S4B, S5C.
Differences in distant metastasis were investigated 
by gross assessment at necropsy and microscopic 
assessment following H&E staining. We observed that 
both PC-3M and PC-3 could disseminate to and establish 
gross macrometastases in a number of distant organs, 
while no visible macrometastases were observed at 
necropsy in mice injected with either LNCaP or C4-2B 
(Figure 4). However, microscopy analysis of lung and 
liver revealed distant metastases to these organs for all 
of the investigated cell lines. Analysis of the incidence 
of gross metastatic disease demonstrated that more 
mesenchymal PC-3M and PC-3 had significantly increased 
metastatic capacity versus more epithelial LNCaP and C4-
2B (p≤0.05) (Figure 5A). Representative H&E and IHC 
analysis of lung metastases are shown in Figure 5B and 
Supplementary Figure S4C. Additionally, the number of 
CTCs was significantly higher across all cell lines in mice 
with metastatic disease relative to those without (p≤0.05) 
(Figure 5C), and in those cell lines with the greatest 
metastatic capacity, thus demonstrating the relationship 
between CTCs and metastatic spread.
Circulating tumor cells acquire a more 
mesenchymal phenotype during disease 
progression
To further investigate the EMT profile of CTCs 
shed into the circulation, blood was used to generate 
CTC sub-lines representing different timepoints along 
the metastatic cascade. Briefly, excess blood, not 
required for CTC assessment, was lysed (NH4Cl), 
washed, and resuspended in cell line specific culture 
medium. Cells were cultured, with frequent media 
changes to remove contaminating white blood cells, 
and subsequently assessed for EMT marker expression 
using immunoblotting. Unfortunately due to low 
numbers of CTCs collected from LNCaP and C4-2B, 
CTC growth following plating did not occur. However 
several sub-lines were created for both PC-3 and PC-
3M. Immunoblot analysis (Figure 6) demonstrated a 
significant reduction in E-cadherin expression in CTCs 
collected at all timepoints compared to the parental PC-3 
(p≤0.05), a trend in reduction of EpCAM expression, 
a significant increase in N-cadherin expression at later 
timepoints (p≤0.05), and a trend towards increasing 
vimentin expression, suggesting CTCs may become more 
mesenchymal as disease progresses.
DISCUSSION
CTCs have emerged as a promising biomarker for 
tracking disease progression and therapy response in 
patients with different types of solid tumors. However, 
although CTCs are now used clinically for prognostication 
in metastatic prostate, breast and colorectal cancer, their 
underlying biology and the complex interplay between 
EMT, CTCs and metastasis remains poorly understood. 
Therefore significant debate remains with regards to which 
CTCs are the most valuable to capture and characterize, 
and which will serve as optimal tools for personalized 
cancer treatment [33]. The lack of knowledge about CTC 
biology stems from both the unique bedside-to-bench 
approach employed in the CTC field and the lack of 
appropriate tools for studying CTCs in vivo in pre-clinical 
metastasis models.
This study aimed to address these gaps through 
development of two novel pre-clinical CTC enumeration 
assays and their implementation for determining 
differences in CTC detection using an epithelial-based 
(EMT-dependent) method and a human versus mouse-
based (EMT semi-independent) approach to assess the 
generation of mesenchymal CTCs that would be missed 
by current technologies, particularly the clinically used 
CSS. Although a previous experimental study examined 
CTCs in mouse models using pre-engineered, fluorescent-
expressing PC-3 PCa cells [34], this is not a clinically-
relevant scenario and thus we instead aimed to assess 
CTCs using assays modeled after those used clinically. 
By leveraging the capabilities of the existing CSS clinical 
platform and taking advantage of the HLA complex in 
separating human from mouse cells, the assays described 
here are the first report of adaptation of the CSS for use 
in xenograft models, without mis-identification of mouse 
epithelial cells. In addition, these assays allow for the 
processing/analysis very low volumes of blood (50μl), 
making these assays amenable to both blood collected at 
necropsy as well as serial monitoring of xenograft models 
in which less than 100μl aliquots of blood can be typically 
collected.
In the current study, assay validation using 
sensitivity/recovery studies demonstrated that the CSS-
based assay failed to detect a significant number (~40-
50%) of mesenchymal CTCs. In vivo, PCa tumors with an 
increasingly mesenchymal phenotype shed greater numbers 
of CTCs more quickly and with greater metastatic capacity 
than those with an epithelial phenotype. Notably, the CSS-
based assay captured the majority of CTCs shed during early-
stage disease regardless of EMT status of the originating 
tumor, and only after the establishment of metastases were 
a significant number of undetectable mesenchymal CTCs 
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Figure 4: Human prostate cancer cell lines with an increasingly mesenchymal phenotype have an enhanced in vivo 
capacity for metastasis to distant organs. Incidence of metastasis to distant organs following orthotopic injection of PC-3M, PC-3, 
LNCaP C4-2B, and LNCaP human prostate cancer cell lines. Data are presented as the percentage of mice per cell line per timepoint with 
detectable distant metastases to the lung, liver diaphragm, intestines, kidney, and/or spleen/pancreas (n=7-39 mice/group) as assessed by 
gross observation at necropsy (left panel) and microscopic histological examination (right panel) of tissues.
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Figure 5: Mesenchymal human prostate cancer cell lines exhibit an enhanced capacity for metastasis that is correlated 
with CTC dissemination. A. Incidence of metastasis to distant organs following orthotopic injection of PC-3M, PC-3, LNCaP C4-
2B, and LNCaP prostate cancer cell lines. Data are presented as the percentage of mice per cell line per timepoint with detectable distant 
metastases (n=7-39 mice/group) as assessed by gross observation at necropsy. B. Representative H&E and IHC (E-cadherin and N-cadherin) 
images of lung metastases for each investigated cell line. Histological sections are presented at 40x magnification. Arrowheads on H&E 
images indicate regions of tumor within the given tissue. Scale bars = 50 μm. C. Correlation of CTC number and incidence of metastasis. 
Mean number of CTCs/50μl of blood, assessed using the EMT semi-independent assay, are presented for mice with either metastasis to 
the lymph nodes or any distant organ (based on gross and/or microscopic analysis) or mice with no evidence of metastasis at any timepoint 
(n=6-47 mice/group). Differences in the incidence of primary tumors, lymph node metastasis, and distant metastasis were assessed using 
Fisher’s Exact Test. Differences in the mean number of CTCs in mice with no metastasis versus those with metastatic disease were 
compared using a Student’s t-test. * = significantly different (p≤0.05), ** (p<0.01), *** (p<0.001).
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present. It is important to note that the EMT semi-independent 
assay, although novel and innovative, is unfortunately not 
adaptable for use with human blood samples. However, 
significant effort is being focused on the development of 
CTC capture techniques capable of recovering not only 
CTCs expressing epithelial markers (EpCAM/CK), but also 
(or even instead) those with a highly mesenchymal phenotype 
[9, 10] in human specimens. This latter pursuit is based on 
the idea that mesenchymal CTCs are the “bad actors”; a 
hypothesis supported by experimental studies demonstrating 
that EMT imparts enhanced invasiveness, metastatic 
capacity, and therapy resistance [9, 10, 12]. Efforts to detect 
Figure 6: Circulating tumor cells acquire a more mesenchymal phenotype during disease progression. Following 
orthotopic injection of PC-3 prostate cancer cells into the right dorsolateral lobe of the prostate (1 × 106 cells/mouse) blood collected at 8 
weeks, 12 weeks, and 16 weeks post-injection was lysed with sterile 1x NH4Cl, washed with PBS, and plated for tissue culture. Following 
1-2 weeks of growth, with regular media changes to remove contaminating blood cells, the remaining CTCs were assessed using immunoblot 
for the expression of the epithelial-associated markers E-cadherin and EpCAM and the mesenchymal-associated markers N-cadherin and 
vimentin. Results are presented in quantitative densitometric form normalized to β-actin and as representative immunoblots, shown as 
cropped gel images (n=3). Changes in EMT gene expression were compared to the parental cell line using 1-way ANOVA with Dunnett’s 
post-test for multiple comparisons. * = significantly different than parental line (p≤0.05).
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these “bad actors” have included the exploitation of various 
properties of CTCs that are either independent or less reliant 
on their EMT status (e.g., size/deformability [microfiltration/
microfluidics], electrical properties [dielectrophoresis], 
immunomagenetic approaches using organ/tumor specific-
antigens [carcinoembyronic antigen (CEA), epidermal 
growth factor receptor (EGFR), prostate specific antigen 
(PSA), mucin-1 (MUC-1)], and adhesion assays based on 
CTCs ability to adhere to the presented capture surface) 
[35]. However, our results demonstrate that although 
prostate tumors with mesenchymal phenotypes shed CTCs 
earlier and in greater numbers than those with epithelial 
phenotypes, the majority these CTCs are still captured by 
the CSS, at least before the establishment of metastatic 
disease. This indicates that CTCs shed early in disease may 
have a hybrid EMT phenotype during dissemination, while 
still expressing sufficient levels of EpCAM and CK8/18/19 
for detection using epithelial-based techniques. Therefore, 
CTCs with an E-M hybrid (rather than purely mesenchymal) 
phenotype may be important for establishing metastasis and 
therefore most interesting to characterize, at least in early-
stage patients. This is supported by observations that CTCs 
with a hybrid phenotype may be of particular importance 
in the clinical setting based on their EMT/MET phenotypic 
plasticity [19].
Our data further demonstrates a significant increase 
in the number of mesenchymal CTCs that are undetectable 
by the CSS following the establishment of distant 
metastases. This increase in mesenchymal characteristics 
of CTCs in late-stage disease has also been demonstrated 
in patients with metastatic versus localized disease [36, 
37]. However, further studies are needed to determine if/
how these undetectable CTCs are contributing to disease 
progression and metastasis. This is because, despite 
widespread speculation, there is little evidence to support 
the hypothesis that highly mesenchymal CTCs have any 
additional prognostic/predictive value compared to hybrid 
E-M or even purely epithelial CTCs in patients. However, 
we must consider that technological limitations related 
to mesenchymal CTC capture may significantly hinder 
testing of this hypothesis in the clinic. In addition, we 
cannot rule out the possibility that highly mesenchymal 
CTCs are present in early-stage disease but not in high 
enough numbers to significantly contribute to differences 
between the 2 CTC assays described. In fact, the cancer 
stem cell (CSC) hypothesis posits that only a fraction of 
cells within the primary tumor efficiently complete the 
metastatic process [38]. Therefore it is possible that the 
dramatic increase in mesenchymal CTCs following the 
development of metastases is due to selective outgrowth 
of CSCs [39]. Thus, although this study provides valuable 
insights into the role of EMT in CTC dissemination/
kinetics, many questions remain, for which the assays 
developed here will be very useful in answering.
In addition to this study’s contributions towards 
understanding CTC biology and its relationship to EMT, to 
our knowledge it is the first comprehensive head-to-head 
comparison of EMT characteristics and in vivo behavior 
(including CTC dissemination/kinetics) of 4 commonly used 
PCa cell lines using orthotopic injection models of PCa. It 
is important to note that the metastatic process may differ 
in in vivo spontaneous metastasis models in comparison 
to the actual disease setting in a patient (e.g., differences 
in the antigen expression/tissue architecture impacting 
intravasation/extravasation, and decreased immune-
surveillance in immune-compromised models) and therefore 
the selection of appropriate metastasis models which best 
recapitulate disease progression and dissemination is an 
important consideration [40–42]. The orthotopic model 
utilized throughout this study provides a much more 
clinically relevant model of CTC production and metastasis 
than more commonly used (and technically less challenging) 
subcutaneous injection models [34]. Based upon this careful 
selection, we anticipate that the data presented here will serve 
as a valuable tool for future PCa research.
Overall, our pre-clinical studies provide important 
translational information that will inform the use of CTCs 
as valuable biomarkers of cancer progression in the clinic. 
In particular, our data highlights that how CTC capture/
characterization is utilized in the clinic may greatly depend on 
disease stage. Specifically, in early-stage patients where CTCs 
could provide tremendous value for predicting metastasis (i.e. 
adjuvant setting), detection of an increased number of CTCs 
may not require technology designed to capture mesenchymal 
CTCs, but instead processing of additional blood (>7.5mL) 
on epithelial-based CTC technologies (e.g., CSS) may suffice 
[43, 44]. In addition, our data supports the idea that primary 
tumors with an increasingly mesenchymal phenotype may 
have enhanced metastatic capacity and therefore the detection 
of CTCs with a hybrid E-M phenotype may be of prognostic/
predictive importance in early-stage patients. In contrast, 
in late-stage disease we have demonstrated a significant 
increase in undetectable and highly mesenchymal CTCs 
after the establishment of distant metastasis. Therefore 
further research in this patient cohort will need to examine the 
functional role of these CTCs versus those with an epithelial 
or hybrid phenotype in disease progression and, importantly, 
in therapy resistance. Taken together, the results presented 
here provide novel and important insight into the functional 
influence of EMT on CTC generation and metastasis in PCa. 
Ultimately a better understanding of CTC biology will aid in 
identifying CTCs that will be most valuable for determining 
individualized treatment of metastatic cancer.
MATERIALS AND METHODS
Cell culture
LNCaP [45] (ATCC, Manassas, VA) and PC-
3M [46] (a gift from Paula Foster, Western University, 
London, ON) human PCa cells were maintained in RPMI-
1640+10% fetal bovine serum (FBS). LNCaP C4-2B [47] 
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[C4-2B] human PCa cells (a gift from Katherine Stemke 
Hale, M.D. Anderson, Houston, TX) were maintained in 
T-media+10% FBS. PC-3 human PCa cells [48] (ATCC) 
were maintained in F12K media+10%FBS. MDA-MB-468 
human breast cancer cells [49] (a gift from Janet Price, 
M.D. Anderson) were maintained in αMEM+10%FBS. 
HeLa human cervical cancer cells [50] (a gift from Jim 
Koropatnick, Western University) were maintained in 
DMEM+10%FBS. Media/reagents and FBS were obtained 
from Life Technologies (Carlsbad, CA) and Sigma (St. 
Louis, MO), respectively. Cell lines were authenticated 
via third-party testing (CellCheck, IDEXX BioResearch, 
Columbia, MO) in December 2015.
Real-time PCR
RNA was isolated using TRIzol (Life Technologies), 
reverse-transcribed and subjected to quantitative reverse-
transcription polymerase chain reactions (qRT-PCR) 
using Brilliant II SYBR Green qPCR Master Mix 
(Agilent Technologies, Santa Clara, CA) on a Stratagene 
Mx3000P (Life Technologies) (primer/cycling details; 
Supplementary Table S1). Samples were normalized 
using pooled qPCR human reference total RNA (Agilent 
Technologies) [51].
Immunoblotting
Cells were harvested by cell scraping (E-cadherin, 
N-cadherin) or trypsinization (vimentin, EpCAM, 
α-catenin) and collected in 1% NP-40 lysis buffer. 
Protein (10μg) was subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto polyvinylidene difluoride membranes 
(PVDF; Millipore, Billerica, MA). Membranes were 
blocked (5% skim milk in TBS-T [Tris-buffered 
saline+0.1%Tween-20]; Sigma). Primary antibodies, 
diluted in 5% skim milk in TBS-T are described 
Supplementary Table S2. Goat-anti-mouse-IgG and 
goat-anti-rabbit-IgG secondary antibodies (Calbiochem, 
Billerica, MA) conjugated to horseradish peroxidase and 
diluted in 5% skim milk in TBS-T were used at 1:2,000 
for all proteins except E-cadherin (1:10,000). Protein 
expression was visualized using Amersham ECL Prime 
Detection Reagent (GE Healthcare, Wauwatosa, WI), and 
normalized to total protein based on amido black (Sigma) 
membrane staining.
Flow cytometry
Cells (5×105) were treated with the IntraPrep™ Fix/
Perm kit (Beckman Coulter, Fullerton, CA, USA) and 
incubated with blocking buffer (PBS/5% BSA [bovine 
serum albumin]); 15min). Cells were incubated with 
primary antibodies (30min) as detailed in Supplementary 
Table S3, followed by incubation with AlexaFluor488-
conjugated goat-anti-mouse IgG or AlexaFluor488-
conjugated goat-anti-rabbit IgG secondary antibodies 
(1μg; Life Technologies). Samples were analyzed using 
an EPICS XL-MCL or Cytomics FC500 flow cytometer 
(Beckman Coulter).
Immunofluorescence
Cells were seeded into glass chamber slides 
(Thermo Scientific) pre-coated with fibronectin (5μg/mL; 
Santa Cruz Biotechnologies, Dallas, TX), grown until 
confluent, fixed with 2% paraformaldehyde, permeabilized 
(0.1% Triton X-100; Sigma) and blocked (PBS/1% BSA; 
1hr) prior to incubation with anti-E-cadherin and/or anti-α-
catenin primary antibodies (1:50; 1hr). Cells were labeled 
with goat-anti-mouse-IgG-AlexaFluor488 and/or goat-
anti-rabbit-IgG-AlexaFluor594 (Life Technologies; 1:300; 
1hr) before mounting with VectaShield+DAPI (Vector 
Laboratories, Burlingame, CA). Imaging was performed 
(60x) using an Olympus Provis AX70 microscope 
(Olympus, Richmond Hill, ON).
Pre-clinical CTC assay development
Whole blood (100μL minimum) was collected 
from 6-8wk old male athymic nude (nu/nu) mice (Harlan 
Sprague-Dawley, Indianapolis, IN) via cardiac puncture 
as described [22, 23]. Blood was processed immediately 
or stored for up to 48 hours with an equal volume 
of CytoChex (Streck, Omaha, NE). For CTC assay 
development, 50μL of blood was “spiked” with 1000 
tumor cells. To assess recovery of low numbers of cells 
(5-100), serial dilutions were performed (data not shown).
The EMT-dependent CTC assay was adapted 
from the Veridex mouse/rat CellCapture kit (no longer 
available) as described previously [52]. Briefly, 50μL 
of whole blood was incubated with components of the 
CellSearch® CTC kit; including anti-EpCAM ferrofluid, 
Capture Enhancement Reagent, Nucleic Acid Dye, 
Staining Reagent, and Permeabilization Reagent. 
Additional reagents included anti-mouse-CD45-APC 
(0.30μg; 30-F11; eBioscience, San Diego, CA), and anti-
human-HLA-AlexaFluor488 (1.5μg; W6/32; BioLegend, 
San Diego, CA). Samples were immune-magnetically 
separated and transferred to a MagNest™ for analysis 
using the CSS. EpCAM+/CK+/DAPI+/CD45-/HLA+ cells 
with a round/oval morphology were classified as CTCs.
Development of the EMT semi-independent CTC 
assay was based on negative selection/immunodepletion of 
CD45+ leukocytes combined with dual staining with human 
HLA and EpCAM. Our initial assay design only employed 
HLA (to take advantage of the human-in-mouse model), 
however we observed that relative levels of HLA present on 
each of the cell lines was highly variable, and in particular 
the EpCAM+ LNCaP and C4-2B cells had low HLA 
compared to PC3 cells (data not shown). Since differences 
in HLA would makes interpretation of CTC capture data 
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very difficult, we took a joint HLA/EpCAM approach 
which detects all CTCs present, including EpCAMlow/- cells 
(PC-3, PC-3M; by HLA) and EpCAM+ but HLAvariable/low 
cells (LNCaP, C4-2B; by EpCAM). For testing, 50μL of 
blood was lysed with NH4Cl. Samples were washed and 
labeled (20min) using anti-human-HLA-PE (0.2μg; W6/32; 
BioLegend), anti-human-EpCAM-PE (0.0075μg; EBA-1; 
BD Bioscience), and anti-mouse-CD45-APC (0.30μg). 
Samples were washed and immunomagnetically enriched 
using the EasySep APC Positive Selection kit (StemCell 
Technologies, Vancouver, BC). The tumor cell fraction was 
incubated (20min) in Permeabilization Reagent (100μL) 
and Nucleic Acid Dye (50μL; Janssen Diagnostics). After 
washing, cells bound by PE-conjugated antibodies (HLA/
EpCAM) were immunomagnetically labelled using the 
EasySep PE Positive Selection kit (StemCell Technologies) 
and transferred to a MagNest™ for analysis using the 
CSS. EpCAM/HLA+/DAPI+/CD45- cells with a round/oval 
morphology were classified as CTCs.
In vivo CTC and metastasis assays
Animal experiments were conducted under protocol# 
2012-031 approved by Western University’s Animal Care 
Committee. PCa cells were prepared in sterile Hank’s 
buffered saline (Life Technologies) and injected (1x106 
cells/40μL per mouse) orthotopically into 6-8wk old male 
athymic nude (nu/nu) mice (Harlan Sprague-Dawley) via 
the right dorsolateral lobe of the prostate as described 
[53, 54]. Briefly, a low midline abdominal incision of 
approximately 3-4 mm was made in anesthetized mice. 
The bladder was gently lifted and the right dorsolateral lobe 
was identified. The cell solution was slowly injected into 
the prostate gland before replacing the bladder and suturing 
the muscle and skin layers closed. At 2,4,8,12 and 16wks 
post-injection, mice were sacrificed, necropsies performed, 
and tissues collected. Prostates and bladders were weighed 
as surrogates of primary tumor volume. Blood (100μL) 
was collected and processed using both CTC assays (50μL/
assay) to assess differences in CTC dissemination and 
kinetics. Whenever possible, CTC sub-cell lines were 
generated using excess blood lysed (NH4Cl) and cultured.
Throughout the study mice were occasionally 
sacrificed at modified timepoints (±1-2wks) due to morbidity 
and/or technical issues. To facilitate statistical analysis, mice 
were categorized based on time of sacrifice (1-3, 4-6, 8-10, 
11-13 or 14-16wks). For simplicity, data is presented at 
the initially defined timepoints (2, 4, 8, 12, 16wks). Due to 
unexpectedly rapid progression of the PC-3M cell line, CTCs 
in this group could only be assessed at 2-4wks.
Histology and immunohistochemistry
At necropsy, tissues were formalin-fixed, paraffin-
embedded, sectioned (4μm) and stained (hematoxylin 
and eosin [H&E]). Serial sections were deparaffinized 
(xylene) and rehydrated (graded series of alcohols 
[100/95/80/75%]) prior to staining. Antigen retrieval was 
performed (10mM sodium citrate buffer/0.05% Tween-20 
[100°C; 20min]) before incubation with BLOXALL 
Endogenous Peroxidase and Alkaline Phosphatase 
Blocking Solution (Vector Laboratories). Staining for 
E-cadherin (1:100) and N-cadherin (1:750) was performed 
(Polink DS-MR-Hu kit [GBI Labs, Bothell, WA]). Slides 
were imaged (40x) using an Aperio ScanScope (Aperio 
Technologies, Vista CA).
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 5.0 (San Diego, CA) and/or SPSS (IBM, Armonk, 
NY) as detailed in Figure Legends, with p≤0.05 considered 
statistically significant.
ACKNOWEDGMENTS
The authors would like to thank Benjamin Hedley 
and Michael Keeney for their help and advice with 
CTC assay development and flow cytometry analysis; 
Madeleine Moussa for her advice with the pathohistologic 
analysis; and Larry Stitt for his assistance with statistical 
data analysis.
CONFLICTS OF INTEREST
A.L.A. has been the recipient of investigator-
initiated research support from Janssen Diagnostics and 
Janssen Oncology (Canada) for clinical studies unrelated 
to the pre-clinical study reported in this manuscript. All 
other authors have no potential conflicts to declare.
GRANT SUPPORT
Funding for this study was provided by a grant 
from Prostate Cancer Canada (to A.L.A.). L.E.L. and 
M.M.P. were supported by graduate scholarships from the 
Canadian Institutes for Health Research (CIHR). A.L.A. 
was supported by a CIHR New Investigator Award and 
an Early Researcher Award from the Ontario Ministry of 
Research and Innovation.
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA 
Cancer J Clin. 2016; 66: 7–30.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination 
and growth of cancer cells in metastatic sites. Nat Rev 
Cancer. 2002; 2: 563–572.
3. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical 
relevance and specific biological properties of disseminating 
tumour cells. Nat Rev Cancer. 2008; 8: 329–340.
Oncotarget76138www.impactjournals.com/oncotarget
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, 
Miller MC, Reuben JM, Doyle G V, Allard WJ, Terstappen 
LWMM, Hayes DF. Circulating tumor cells, disease 
progression, and survival in metastatic breast cancer. N 
Engl J Med. 2004; 351: 781–791.
5. Cohen SJ, Punt CJ a, Iannotti N, Saidman BH, Sabbath KD, 
Gabrail NY, Picus J, Morse M a, Mitchell E, Miller MC, 
Doyle G V, Tissing H, Terstappen LWMM, et al. Prognostic 
significance of circulating tumor cells in patients with 
metastatic colorectal cancer. Ann Oncol. 2009; 20: 1223–1229.
6. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller 
MC, Tissing H, Doyle G V, Terstappen LWWM, Pienta KJ, 
Raghavan D. Circulating tumor cells predict survival benefit 
from treatment in metastatic castration-resistant prostate 
cancer. Clin Cancer Res. 2008; 14: 6302–6309.
7. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu 
T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci 
MA, Monk JP, Datar RH, Garzotto M, et al. Circulating 
tumor cell counts are prognostic of overall survival in 
SWOG S0421: a phase III trial of docetaxel with or without 
atrasentan for metastatic castration-resistant prostate cancer. 
J Clin Oncol. 2014; 32: 1136–1142.
8. Allan AL, Keeney M. Circulating tumor cell analysis: 
technical and statistical considerations for application to 
the clinic. J Oncol. 2010; 2010: 426218.
9. Lowes LE, Allan AL. Recent advances in the molecular 
characterization of circulating tumor cells. Cancers (Basel). 
2014; 6: 595–624.
10. Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor 
cell technologies. Mol Oncol. 2016; 10: 374–394.
11. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, 
Rao C, Tibbe AGJ, Uhr JW, Terstappen LWMM. Tumor cells 
circulate in the peripheral blood of all major carcinomas 
but not in healthy subjects or patients with nonmalignant 
diseases. Clin Cancer Res. 2004; 10: 6897–6904.
12. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-
mesenchymal transitions in development and disease. Cell. 
2009; 139: 871–890.
13. Joosse SA, Gorges TM, Pantel K. Biology, detection, and 
clinical implications of circulating tumor cells. EMBO Mol 
Med. 2015; 7: 1–11.
14. Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob 
E, Onuchic JN, Levine H. Implications of the Hybrid 
Epithelial/Mesenchymal Phenotype in Metastasis. Front 
Oncol. 2015; 5: 155.
15. Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, 
Krahn T, von Ahsen O. Circulating tumour cells escape 
from EpCAM-based detection due to epithelial-to-
mesenchymal transition. BMC Cancer. 2012; 12: 178.
16. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, 
Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann 
LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. 
Immune-induced epithelial to mesenchymal transition 
in vivo generates breast cancer stem cells. Cancer Res. 
2009; 69: 2887–2895.
17. Yang J, Weinberg R a. Epithelial-mesenchymal transition: 
at the crossroads of development and tumor metastasis. Dev 
Cell. 2008; 14: 818–829.
18. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, 
Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon 
KF, Donaldson MC, Sequist L V, et al. Circulating breast 
tumor cells exhibit dynamic changes in epithelial and 
mesenchymal composition. Science. 2013; 339: 580–584.
19. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting 
RL, Turnbull JD, Herold CI, Marcom PK, George DJ, 
Garcia-Blanco M a. Circulating tumor cells from patients 
with advanced prostate and breast cancer display both 
epithelial and mesenchymal markers. Mol Cancer Res. 
2011; 9: 997–1007.
20. Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, 
Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, 
Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, et al. 
In patients with metastatic breast cancer the identification 
of circulating tumor cells in epithelial-to-mesenchymal 
transition is associated with a poor prognosis. Breast Cancer 
Res. 2016; 18: 30.
21. Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, 
Vielh P, Fizazi K, Massard C, Farace F. Vimentin and Ki67 
expression in circulating tumour cells derived from castrate-
resistant prostate cancer. BMC Cancer. 2016; 16: 168.
22. Goodale D, Phay C, Postenka CO, Keeney M, Allan AL. 
Characterization of tumor cell dissemination patterns 
in preclinical models of cancer metastasis using flow 
cytometry and laser scanning cytometry. Cytometry A. 
2009; 75: 344–355.
23. Allan AL, Vantyghem S a, Tuck AB, Chambers AF, Chin-Yee 
IH, Keeney M. Detection and quantification of circulating 
tumor cells in mouse models of human breast cancer using 
immunomagnetic enrichment and multiparameter flow 
cytometry. Cytometry A. 2005; 65: 4–14.
24. Lowes LE, Goodale D, Keeney M, Allan AL. Image 
cytometry analysis of circulating tumor cells. Methods Cell 
Biol. 2011; 102: 261–290.
25. Stephenson RA, Dinney CP, Gohji K, Ordóñez NG, Killion 
JJ, Fidler IJ. Metastatic model for human prostate cancer 
using orthotopic implantation in nude mice. J Natl Cancer 
Inst. 1992; 84: 951–957.
26. Shah G V., Thomas S, Muralidharan A, Liu Y, Hermonat 
PL, Williams J, Chaudhary J. Calcitonin promotes in vivo 
metastasis of prostate cancer cells by altering cell signaling, 
adhesion, and inflammatory pathways. Endocr Relat Cancer. 
2008; 15: 953–964.
27. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, 
Keller ET. Effects of raf kinase inhibitor protein expression 
on suppression of prostate cancer metastasis. J Natl Cancer 
Inst. 2003; 95: 878–889.
Oncotarget76139www.impactjournals.com/oncotarget
28. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson 
MR, Killion JJ, Fidler IJ. Selection of Highly Metastatic 
Variants of Different Human Prostatic Carcinomas Using 
Orthotopic Implantation in Nude Mice. Clin Cancer Res. 
1996; 2: 1627–1636.
29. Nagafuchi A, Takeichi M. Cell binding function of 
E-cadherin is regulated by the cytoplasmic domain. EMBO 
J. 1988; 7: 3679–3684.
30. Ozawa M, Ringwald M, Kemler R. Uvomorulin-catenin 
complex formation is regulated by a specific domain in the 
cytoplasmic region of the cell adhesion molecule. Proc Natl 
Acad Sci U S A. 1990; 87: 4246–4250.
31. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs 
WB. Reduction of E-cadherin levels and deletion of the 
alpha-catenin gene in human prostate cancer cells. Cancer 
Res. 1993; 53: 3585–3590.
32. Gosens MJEM, van Kempen LCL, van de Velde CJH, 
van Krieken JHJM, Nagtegaal ID. Loss of membranous 
Ep-CAM in budding colorectal carcinoma cells. Mod 
Pathol. 2007; 20: 221–232.
33. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. 
Circulating tumor cells: a multifunctional biomarker. Clin 
Cancer Res [Internet]. 2014; 20: 2553–2568.
34. Glinskii AB, Smith BA, Jiang P, Li X-M, Yang M, Hoffman 
RM, Glinsky G V. Viable circulating metastatic cells 
produced in orthotopic but not ectopic prostate cancer 
models. Cancer Res. 2003; 63: 4239–4243.
35. Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. 
Circulating Tumor Cells: A Review of Non-EpCAM-Based 
Approaches for Cell Enrichment and Isolation. Clin Chem. 
2016; 62: 571–581.
36. Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, 
Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki 
S. Co-expression of putative stemness and epithelial-to-
mesenchymal transition markers on single circulating 
tumour cells from patients with early and metastatic breast 
cancer. BMC Cancer. 2014; 14: 1–10.
37. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias 
V, Agelaki S. Epithelial to mesenchymal transition markers 
expressed in circulating tumour cells of early and metastatic 
breast cancer patients. Breast Cancer Research. 2011. p. R59.
38. Croker AK, Allan AL. Cancer stem cells: implications for 
the progression and treatment of metastatic disease. J Cell 
Mol Med. 2008; 12: 374–390.
39. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger 
A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, 
Wallwiener M, Holland-Letz T, Höfner T, Sprick M, et al. 
Identification of a population of blood circulating tumor 
cells from breast cancer patients that initiates metastasis in 
a xenograft assay. Nat Biotechnol. 2013; 31: 539–544.
40. Khanna C, Hunter K. Modeling metastasis in vivo. 
Carcinogenesis. 2005; 26: 513–523.
41. Richmond A, Su Y. Mouse xenograft models vs GEM models 
for human cancer therapeutics. Dis Model Mech. 1: 78–82.
42. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse 
models of advanced spontaneous metastasis for experimental 
therapeutics. Nat Rev Cancer. 2011; 11: 135–141.
43. Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp 
P, Zwingers T, Friedl TWP, Lorenz R, Tesch H, Fasching PA, 
Fehm T, Schneeweiss A, Lichtenegger W, et al. Circulating 
tumor cells predict survival in early average-to-high risk 
breast cancer patients. J Natl Cancer Inst. 2014; 106.
44. Janni WJ, Rack B, Terstappen LWMM, Pierga J-Y, Taran 
F-A, Fehm T, Hall C, de Groot MR, Bidard F-C, Friedl TWP, 
Fasching PA, Brucker SY, Pantel K, et al. Pooled Analysis 
of the Prognostic Relevance of Circulating Tumor Cells in 
Primary Breast Cancer. Clin Cancer Res. 2016; 22: 2583-2593.
45. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, 
Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya 
SK, Sandberg AA. The LNCaP cell line--a new model for 
studies on human prostatic carcinoma. Prog Clin Biol Res. 
1980; 37: 115–132.
46. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn 
ME, Hart IR. Metastatic behavior of human tumor cell 
lines grown in the nude mouse. Cancer Res. 1984; 44: 
3522–3529.
47. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim 
EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung 
LW. Androgen-independent cancer progression and bone 
metastasis in the LNCaP model of human prostate cancer. 
Cancer Res. 1994; 54: 2577–2581.
48. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. 
Establishment and characterization of a human prostatic 
carcinoma cell line (PC-3). Invest Urol. 1979; 17: 16–23.
49. Price JE, Polyzos A, Zhang RD, Daniels LM. 
Tumorigenicity and metastasis of human breast carcinoma 
cell lines in nude mice. Cancer Res. 1990; 50: 717–721.
50. Scherer WF, Syverton JT, Gey GO. Studies on the 
propagation in vitro of poliomyelitis viruses. IV. Viral 
multiplication in a stable strain of human malignant 
epithelial cells (strain HeLa) derived from an epidermoid 
carcinoma of the cervix. J Exp Med. 1953; 97: 695–710.
51. Pfaffl M. Quantification strategies in real-time PCR Michael W. 
Pfaffl. In: Bustin SA, editor. A-Z of quantitative PCR. 1st ed. 
La Jolia: International University Line (IUL); 2004. p. 87–112.
52. Lowes LE, Hedley BD, Keeney M, Allan AL. Adaptation 
of semiautomated circulating tumor cell (CTC) assays for 
clinical and preclinical research applications. J Vis Exp. 
2014; : e51248.
53. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang 
SM, Ozen M, Pathak S, Chung LWK. LNCaP progression 
model of human prostate cancer: Androgen-independence 
and osseous metastasis. Prostate. 2000; 44: 91–103.
54. Valta MP, Tuomela J, Vuorikoski H, Loponen N, Väänänen 
RM, Pettersson K, Väänänen HK, Härkönen PL. FGF-8b 
induces growth and rich vascularization in an orthotopic 
PC-3 model of prostate cancer. J Cell Biochem. 2009; 107: 
769–784.
